TrialPath

17 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

16 studies on the map

Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis — Southern Arizona VA Health Care System, Tucson, AZ, TucsonA Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease — Barrow Neurological Institute, PhoenixOcrelizumab Discontinuation in Relapsing Multiple Sclerosis — Yale School of Medicine, New HavenProspective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod — University of Colorado Anschutz Medical Campus, AuroraComparing Antipsychotic Medications in LBD Over Time — University Health System, San AntonioCortical Electrophysiology of Response Inhibition in Parkinson's Disease — Emory University Hospital, AtlantaElucidating the Role of Cholinergic Degeneration in Cognitive Fluctuations in Lewy Body Dementia — Virginia Commonwealth University, RichmondBOOST-PD A Naturalistic Study on IPX-203 for Parkinson's Disease — Cleveland Clinic, ClevelandCharacterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases — Vanderbilt University Medical Center, NashvillePersonalized Real-Time DBS and PD Mechanisms — Cleveland Clinic, ClevelandUblituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis — Northwestern Memorial Hospital, ChicagoGlucose Consumption in MS Using [F-18]FDG-PET — Brigham & Women's Hospital, BostonDalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis — MGH Institute of Health Professions, BostonSilodosin for Urinary Symptoms in Female Patients With Multiple Sclerosis — Atlantic Health, MorristownHome Based Infusions for Ocrelizumab — Amerita, CentennialStudy of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis — Johns Hopkins University, Baltimore